Provectus announces presentation of preclinical data on PV-10

Provectus Biopharmaceuticals announced that data from preclinical research by Moffitt Cancer Center on PV-10 for the treatments of human papillomavirus-positive and HPV-negative head and neck squamous cell carcinoma were presented at the annual meeting of the American Association for Cancer Research) held April 5-10, 2024 in San Diego, California. Titled PV-10 triggers immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma via endoplasmic reticulum stress and autophagy, a copy of Moffitt’s poster presentation is available on Provectus’s website. This work has been part of research conducted by Christine Chung, M.D., Chair, Department of Head and Neck-Endocrine Oncology and Program Leader of Head and Neck Oncology and members of the Chung laboratory at Moffitt in Tampa, Florida. Moffitt observed that PV-10 induced reactive oxygen species-mediated apoptosis, surface expression of calreticulin, and extracellular ATP and HMGB1 release in HNSCC cells. PV-10-induced immunogenic cell death led to surface expression of HSP-70 and HSP-90 in these cells. Intralesional injection of PV-10 promoted tumor regression in mice by inducing endoplasmic reticulum stress, triggering autophagy, and initiating apoptosis. Moffitt concluded that PV-10 demonstrated significant anti-tumor activity in HNSCC. In vitro studies illustrated that PV-10 induced potent ICD in HNSCC cells, and in vivo experiments showed that IL PV-10 led to substantial tumor regression and complete responses in some mice. These findings, according to Moffitt, underscored the significance of PV-10-induced ICD, which may offer a novel and promising approach for managing HNSCC and potentially pave the way for improved survival rates and reduced adverse events.